



Medicines Control Authority of Zimbabwe

Circular 26 of 2023 (Processing Applications for Registration of Medicines) Update

11 OCTOBER 2024

GRACE MATIMBA: CHIEF REGULATORY OFFICER: EVALUATIONS



Outline

1. Background

2. Update

3. Achievements

4. Challenges

5. Next Steps

MCAZ's Mandate

Protect and Promote Public Health & Animal Health

By assuring that medical products marketed in the country are **SAFE, EFFECTIVE and of **GOOD QUALITY****

Concerns from stakeholders

- Timeline to regulatory decision
- Processing of applications that were submitted prior to 2024
- Payment of resubmission fees
- Finalisation of intent to register responses
- FIFO
- Poor communication



BACKGROUND



Mapping Exercise July – Sept 2023

- ☐ Human Allopathic Medicines Unit (950 pending)

398: opened files and 552: unopened files

- ☐ Veterinary Medicine Unit (40 pending)

- ☐ Complementary Medicines Unit (120 pending)

Circular 26 of 2023

Observations

- ❑ Submission of substandard application for registration
- ❑ Multiple deadline requests
- ❑ Protracted Review Cycle: ≥ 6
- ❑ Increase in WIP: Reduction in Productivity
- ❑ General increase x3 in applications for registration
- ❑ Perennial Staff Attrition: Reduction in Talent
- ❑ Inefficient Tracking & Monitoring of Timelines



Circular 26 of 2023

Solution

- ❑ High level Screening
- Pass:** Proceed to evaluate
- Fail:** NMT 120 respond
- ❑ Limit Review Cycles ≤ 2
- ❑ Regulatory Decision in NMT 9 months
- ❑ Previous Median Time to Registration 24 months

that are yet to be assessed. To avoid further inefficiencies resulting from implementing multiple processes, these applications will also be screened prior to assessment, even though they have already been accepted and issued with Application numbers.

Applications failing screening

Applications that fail screening will be allocated with **Quarantine numbers**. A Quarantine number in essence means that the application is held in abeyance pending resolution by the Applicant of shortcomings noted during the screening process. **It is critical to note that there is no priority afforded to quarantined applications.**

Once an application is quarantined, the Authority will issue a letter to the applicant, intending to refuse to register the product, unless a complete application is submitted within 120 days. Failure by the Applicant to resubmit a complete application within the prescribed timelines will result in refusal to register the application and Applicants interested in pursuing such applications will be required to resubmit new applications accompanied by payment of the full application fee.

Upon resubmission of a complete dossier and payment of the statutory resubmission fees as stipulated in item 7(a)(ix), 7(b)(v) and 7(c)(iv) of the MCAZ Fee Schedule, applications will undergo a second round of screening. **Applications that fail the second round of screening will be refused registration without assessment.** It is also critical to note that in computation of the Authority's timelines, quarantined products will be tracked separately from complete applications.

Applications passing screening

Application numbers will **ONLY** be allocated to complete applications that pass screening at first attempt or those that pass screening following resubmission of a complete dossier and payment of statutory resubmission fees as discussed above. **Only complete applications that are issued with application numbers will be admitted for assessment.**

Review cycles

With immediate effect, stakeholders are advised that the Authority will conduct a maximum of two (2) review cycles per product before reaching a **final regulatory decision** (*registration or refusal to register*). Applicants are advised to take all issues raised in the assessment report seriously to avoid exceeding the maximum number of review cycles. At the end of the 1st review cycle, applicants will be further advised to withdraw their applications **voluntarily** if they cannot address the queries raised by the Authority. The Authority will reach a final regulatory decision at the end of the 2nd cycle.

Registration process regulatory phases

With immediate effect, the Authority will use a tracker (clock start-clock stop system) to efficiently monitor and track each application as a separate project as indicated below:

Phase	Submission	Screening	1 st Assessment Cycle	Submission of 1 st Response	2 nd Assessment Cycle	Final Regulatory Decision	Post-Decision
Activity	Applicant submits Dossier	High level screening by MCAZ assessors	1 st Assessment session by MCAZ	Applicant submits Response	2 nd Assessment session by MCAZ	Final Committee decision	Administrative and Regulatory activities

Circular 26 of 2023

Anticipated Benefits

- ❑ Increase in efficiency in processing applications for registration
- ❑ Improvements in submissions: MCAZ/ICH Requirements
- ❑ Significant reduction in timelines for registration
- ❑ Efficient Talent Management
- ❑ Better Risk-Based Assessments on Quality submissions
- ❑ Abolishment of the tendency to hold queue by applicants with grossly deficient dossiers

Phase	Submission	Screening	1 st Assessment Cycle	Submission of 1 st Response	2 nd Assessment Cycle	Final Regulatory Decision	Post-Decision
Regulatory requirements	MCAZ CTD Dossier Samples fees	Screening check list	Evaluation report Query letter	MCAZ CTD Dossier	Evaluation report	Evaluation report	Registration Certificate or Letter

Deadline extension request

With immediate effect, the Authority will not entertain any time-extension requests to respond to queries. Any such requests will be rejected and the application will be refused registration. The Authority will strictly monitor and track the following timelines following the Committee decisions:

Authority's Decision	Applicant's Timeline
Intent to refuse to register	60 calendar days
Intent to register	30 calendar days


Anticipated impact of the above measures

We trust that these measures will improve the efficiency of our processes by providing for the following:


1. Reduction in the accumulation of WIP, thereby increasing efficiency.
2. Compelling Applicants to work on updating their dossiers in accordance with the MCAZ and ICH guidelines prior to submitting their applications.
3. Significant reduction in timelines due to the reduced number of review cycles as well as the removal of deadline extensions.
4. More efficient use of assessors' time – assessors are an expensive and scarce resource, and any increase in their efficiency results in an overall increase in the efficiency of the whole system.
5. Assessors spend more time addressing matters of regulatory science, which impact on quality, safety and efficacy of medicines, as opposed to focusing on deficiencies in the product dossier.
6. An increase in the quality of submissions, which enables the Authority to better apply risk-based assessment techniques, which further improve the speed with which applications are processed.
7. Abolition of the tendency by some applicants to submit incomplete applications in a bid to hold positions in the "queue" of pending applications, and only committing to working on the applications once they receive query letters from the Authority. Under the new process, submitting incomplete applications will not only be costly, but will also proffer no benefits due to the quarantine process, which effectively abolishes the queue.

Yours faithfully,

MEDICINES CONTROL AUTHORITY OF ZIMBABWE


T. Rukwata (Mr.)
DIRECTOR-GENERAL

Screening Decision Matrix



UPDATE

As at 30 September 2024

246 applications have been received

From the received applications, all eligible for screening have been screened

Achievements



IN SEPTEMBER 2024 GREATER
THAN 90% OF SCREENED
APPLICATIONS WERE GRANTED AN
INTENT TO REGISTER AFTER THE
FIRST REVIEW CYCLE



AS AT 30 SEPTEMBER MORE
PRODUCT REGISTRATIONS
COMPARED TO THE PAST 3 YEARS



BETTER AND COMPLETE DOSSIERS
FROM APPLICANTS

CHALLENGES

- Intent to register responses
- Emails are not being responded to allow for finalisation of applications
- Conditions for registration are not being accepted
- Certificate template not being completed
- Information change at registration in the MC8 form or on the certificate
- Labelling requirements taking long to be finalised
- Mitigation: Refusal of applications



CHALLENGES

Responses to screening not meeting deadlines

Mitigation

Refusal of applications, both intent to refuse and proceed to evaluate after screening

Applications for which responses are overdue by **30 November 2024** will be refused registration for failure to respond within deadlines



CHALLENGES – Human Capital

Human allopathic
medicines, Pre-
registration: 6
officers

Veterinary
medicines: 2
officers

Complementary
medicines: 4
officers

Post registration
(variations and
re-registrations):
5 officers

Expedited
projects: 3
officers

CHALLENGES – Human Capital



- Of the 20 technical officers
- 4 officers: > 5 years
- 3 officers: > 2 years
- 7 officers: 1 – 2 years
- 6 officers: 0 – 4 months
- High staff turnover
- Mitigation
- 3 officers joining the unit in November
- Discussions to increase in staff complement
- Intensive training programme

Challenges: Communication Channels



Technical staff burdened with low payoff activities such as high volumes of emails

- Applicants sending responses to the officers who would have sent them an email to collect the letter (remember high turnover)
- Applicants sending an email to every officer they know in the division (also leading to poor response)
- Low payoff activities taking valuable assessors' time

Mitigation

Centralisation of communication

Applicants will be notified of the communication pathways

NEXT STEPS



1. 2022 to 2026 MCAZ strategic goal: full automation of regulatory processes
 - 2024 applications hybrid
 - 2025 real time communication tracking regulatory milestone
 - (receipt, screening, evaluation and regulatory decision)
 - January 2025 electronic submission portal open
2. Manual tracking of applications that came prior to 2024
3. Public assessment reports
4. Re-registrations
5. Screening procedure implemented in 2024 will continue



